<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04218552</url>
  </required_header>
  <id_info>
    <org_study_id>AD-209P2</org_study_id>
    <nct_id>NCT04218552</nct_id>
  </id_info>
  <brief_title>Determining the Optimal Dose of AD-209 in Patients With Essential Hypertension</brief_title>
  <official_title>A Randomized, Double-Blind, Parallel, Multi-Center, Phase 2 Clinical Trial to Determine the Optimal Dose of AD-209 in Patients With Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Addpharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Addpharma Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the optimal dose of AD-209 in patients with
      Essential Hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Condition or disease : hypertension Intervention/treatment Drug : AD-209-H Drug : AD-209-M
      Drug : AD-209-L Drug : Placebo Drug : Amlodipine Drug : Telmisartan Phase : Phase 2
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 28, 2020</start_date>
  <completion_date type="Anticipated">July 28, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 28, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1. Change rate of MSSBP</measure>
    <time_frame>[ Time Frame: baseline, 8 weeks ]</time_frame>
    <description>Change from baseline in mean sitting systolic blood pressure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1. Change rate of MSSBP</measure>
    <time_frame>[ Time Frame: baseline, 4 weeks ]</time_frame>
    <description>Change from baseline in mean sitting systolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2. Change rate of MSDBP</measure>
    <time_frame>[ Time Frame: baseline, 4 weeks, 8 weeks ]</time_frame>
    <description>Change from baseline in mean sitting diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3. Proportion of BP normalization MSSBP/MSDBP ＜ 140/90 mmHg MSSBP/MSDBP ＜ 130/80 mmHg (Diabetes or Chronic renal disease)</measure>
    <time_frame>[ Time Frame: 4 weeks, 8 weeks ]</time_frame>
    <description>Proportion of subjects achieving blood pressure control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4.Reaction rate of BP</measure>
    <time_frame>[ Time Frame: baseline, 4 weeks, 8 weeks ]</time_frame>
    <description>Proportion of reduction from baseline in MSSBP/MSDBP ≥ 20/10 mmHg</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">175</enrollment>
  <condition>Hypertension,Essential</condition>
  <arm_group>
    <arm_group_label>Experimental 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AD-209 High</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AD-209 Middle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AD-209 Low</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amlodipine Low</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amlodipine High</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Telmisartan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AD209</intervention_name>
    <description>PO, Once daily(QD), 8weeks</description>
    <arm_group_label>Experimental 1</arm_group_label>
    <arm_group_label>Experimental 2</arm_group_label>
    <arm_group_label>Experimental 3</arm_group_label>
    <arm_group_label>Placebo comparator</arm_group_label>
    <other_name>AD209 Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine low</intervention_name>
    <description>PO, Once daily(QD), 8weeks</description>
    <arm_group_label>Active Comparator 1</arm_group_label>
    <arm_group_label>Placebo comparator</arm_group_label>
    <other_name>Amlodipine low placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine high</intervention_name>
    <description>PO, Once daily(QD), 8weeks</description>
    <arm_group_label>Active Comparator 2</arm_group_label>
    <arm_group_label>Placebo comparator</arm_group_label>
    <other_name>Amlodipine high placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan</intervention_name>
    <description>PO, Once daily(QD), 8weeks</description>
    <arm_group_label>Active Comparator 3</arm_group_label>
    <arm_group_label>Placebo comparator</arm_group_label>
    <other_name>Telmisartan placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Other inclusions applied

        Exclusion Criteria:

          -  orthostatic hypotension with symptom

          -  Other exclusions applied
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ChangGu Park, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Guro Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>kyungtae kim, D.V.M</last_name>
    <phone>031-891-5661</phone>
    <email>ktkim@addpharma.co.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Si-Beum Lee, Ph.D</last_name>
  </overall_contact_backup>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 3, 2020</study_first_submitted>
  <study_first_submitted_qc>January 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2020</study_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Essential Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Telmisartan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

